...
search icon
crnx-img

Crinetics Pharmaceuticals Inc, Common Stock

CRNX

NSQ

$29.76

-$0.35

(-1.16%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.93B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
740.33K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.32
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$24.1 L
$62.53 H
$29.76

About Crinetics Pharmaceuticals Inc, Common Stock

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCRNXSectorS&P500
1-Week Return-4.74%-1.91%-1.87%
1-Month Return-8.06%-3.82%8.93%
3-Month Return-14.04%-11.56%-2.39%
6-Month Return-46.94%-10.21%-2.41%
1-Year Return-38.8%-9.91%10.88%
3-Year Return47.77%-0.28%46.93%
5-Year Return68.9%31.29%94.89%
10-Year Return21.42%75.9%177.5%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue71.00K1.08M4.74M4.01M1.04M[{"date":"2020-12-31","value":1.5,"profit":true},{"date":"2021-12-31","value":22.76,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.72,"profit":true},{"date":"2024-12-31","value":21.93,"profit":true}]
Cost of Revenue57.00M1.26M1.39M1.10M2.79M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.21,"profit":true},{"date":"2022-12-31","value":2.44,"profit":true},{"date":"2023-12-31","value":1.93,"profit":true},{"date":"2024-12-31","value":4.89,"profit":true}]
Gross Profit71.00K1.08M4.74M4.01M(1.75M)[{"date":"2020-12-31","value":1.5,"profit":true},{"date":"2021-12-31","value":22.76,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.72,"profit":true},{"date":"2024-12-31","value":-36.86,"profit":false}]
Gross Margin100.00%100.00%100.00%100.00%(168.05%)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-168.05,"profit":false}]
Operating Expenses74.95M108.78M172.62M226.62M339.89M[{"date":"2020-12-31","value":22.05,"profit":true},{"date":"2021-12-31","value":32,"profit":true},{"date":"2022-12-31","value":50.79,"profit":true},{"date":"2023-12-31","value":66.67,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(74.95M)(107.70M)(167.88M)(222.61M)(338.85M)[{"date":"2020-12-31","value":-7495300000,"profit":false},{"date":"2021-12-31","value":-10770200000,"profit":false},{"date":"2022-12-31","value":-16788200000,"profit":false},{"date":"2023-12-31","value":-22260800000,"profit":false},{"date":"2024-12-31","value":-33885400000,"profit":false}]
Total Non-Operating Income/Expense2.13M218.00K8.28M21.52M81.88M[{"date":"2020-12-31","value":2.6,"profit":true},{"date":"2021-12-31","value":0.27,"profit":true},{"date":"2022-12-31","value":10.11,"profit":true},{"date":"2023-12-31","value":26.28,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(73.81M)(107.64M)(163.92M)(214.53M)(298.41M)[{"date":"2020-12-31","value":-7381200000,"profit":false},{"date":"2021-12-31","value":-10764100000,"profit":false},{"date":"2022-12-31","value":-16391800000,"profit":false},{"date":"2023-12-31","value":-21452900000,"profit":false},{"date":"2024-12-31","value":-29840800000,"profit":false}]
Income Taxes(948.00K)(922.00K)(3.96M)930.11K-[{"date":"2020-12-31","value":-101.92,"profit":false},{"date":"2021-12-31","value":-99.13,"profit":false},{"date":"2022-12-31","value":-426.19,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(72.86M)(106.72M)(159.95M)(215.46M)-[{"date":"2020-12-31","value":-7286400000,"profit":false},{"date":"2021-12-31","value":-10671900000,"profit":false},{"date":"2022-12-31","value":-15995400000,"profit":false},{"date":"2023-12-31","value":-21545910500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(73.81M)(107.64M)(163.92M)(214.53M)(298.41M)[{"date":"2020-12-31","value":-7381200000,"profit":false},{"date":"2021-12-31","value":-10764100000,"profit":false},{"date":"2022-12-31","value":-16391800000,"profit":false},{"date":"2023-12-31","value":-21452900000,"profit":false},{"date":"2024-12-31","value":-29840800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(72.86M)(106.72M)(159.95M)(214.53M)(298.41M)[{"date":"2020-12-31","value":-7286400000,"profit":false},{"date":"2021-12-31","value":-10671900000,"profit":false},{"date":"2022-12-31","value":-15995400000,"profit":false},{"date":"2023-12-31","value":-21452900000,"profit":false},{"date":"2024-12-31","value":-29840800000,"profit":false}]
EPS (Diluted)(2.46)(2.80)(3.14)(3.70)(3.71)[{"date":"2020-12-31","value":-246,"profit":false},{"date":"2021-12-31","value":-280,"profit":false},{"date":"2022-12-31","value":-314,"profit":false},{"date":"2023-12-31","value":-370,"profit":false},{"date":"2024-12-31","value":-371,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CRNX
Cash Ratio 22.23
Current Ratio 22.53

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CRNX
ROA (LTM) -20.13%
ROE (LTM) -30.84%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CRNX
Debt Ratio Lower is generally better. Negative is bad. 0.08
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.92

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CRNX
Trailing PE NM
Forward PE NM
P/S (TTM) 3668.32
P/B 2.22
Price/FCF NM
EV/R 2058.70
EV/Ebitda NM

FAQs

What is Crinetics Pharmaceuticals Inc share price today?

Crinetics Pharmaceuticals Inc (CRNX) share price today is $29.76

Can Indians buy Crinetics Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Crinetics Pharmaceuticals Inc (CRNX) on Vested. To buy Crinetics Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRNX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Crinetics Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Crinetics Pharmaceuticals Inc (CRNX) via the Vested app. You can start investing in Crinetics Pharmaceuticals Inc (CRNX) with a minimum investment of $1.

How to invest in Crinetics Pharmaceuticals Inc shares from India?

You can invest in shares of Crinetics Pharmaceuticals Inc (CRNX) via Vested in three simple steps:

  • Click on Sign Up or Invest in CRNX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Crinetics Pharmaceuticals Inc shares
What is Crinetics Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Crinetics Pharmaceuticals Inc (CRNX) is $62.53. The 52-week low price of Crinetics Pharmaceuticals Inc (CRNX) is $24.1.

What is Crinetics Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Crinetics Pharmaceuticals Inc (CRNX) is 2.22

What is the Market Cap of Crinetics Pharmaceuticals Inc?

The market capitalization of Crinetics Pharmaceuticals Inc (CRNX) is $2.93B

What is Crinetics Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Crinetics Pharmaceuticals Inc is CRNX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top